Answers are grounded in this paper and cite their sources.
Three advances necessary to bring dolastatin 16 (1) into full-scale preclinical development as an anticancer drug have been accomplished. The X-ray crystal structure of dolastatin 16 has been solved, which allowed stereoselective syntheses of its two new amino acid units, dolamethylleuine (Dml) and dolaphenvaline (Dpv), to be completed. The X-ray crystal structures of synthetic Z-Dml and TFA-Dpv have also been completed.
No takes yet. Share an insight, caveat, or question.
Pettit et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: